Epstein-Barr virus and the immune system: Hide and seek

JAMA

Volumn 278, Issue 6, 1997, Pages 510-513

  Cohen, Jeffrey I ^a,b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINATE CALCIUM; IFOSFAMIDE; MESNA; METHOTREXATE; VINCRISTINE SULFATE;

ADULT; ARTICLE; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; EPSTEIN BARR VIRUS; HUMAN; IMMUNOPATHOGENESIS; INFECTIOUS COMPLICATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; VIRUS INFECTION; VIRUS PATHOGENESIS;

EID: 0030761670     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.6.510     Document Type: Article

References (24)

1. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, et al, eds. Field's Virology. Philadelphia, Pa: Lippincott-Raven; 1996:2397-2446.
2. Straus SE, Cohen JI, Tosato G, Meier J. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med. 1992;118:45-58.
3. Kieff E. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Howley PM, et al, eds. Field's Virology. Philadelphia, Pa: Lippincott-Raven; 1996:2343-2396.
4. Tierney RJ, Steven N, Young LS, Rickinson AB. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol. 1994;68:7374-7385.
5. Chen F, Zou J-Z, diRenzo L, et al. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol. 1995;69:3752-3758.
6. Cohen JI. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine. 1991;70:137-160.
7. Young L, Alfieri C, Hennessy K, et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med. 1989;321:1080-1085.
8. Moore KW, Vieira P, Fiorentino DF, et al. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRF1. Science. 1990;248:1230-1234.
9. Hsu D-H, Malefyt RDW, Fiorentino DF, et al. Expression of interleukin 10 activity by Epstein-Barr virus protein BCRF1. Science. 1990;250:830-832.
10. Swaminathan S, Kieff E. The role of BCRF1/vIL-10 in the life cycle of Epstein-Barr virus. In: McFadden G, ed. Viroceptors, Virokines, and Related Immune Modulators Encoded by DNA Viruses. Austin, Tex: RG Landes Co; 1994:111-125.
11. Springer TA. Adhesion receptors of the immune system. Nature. 1990;346:425-434.
12. Rooney CM, Rowe M, Wallace LE, Rickinson AB. Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T cell surveillance. Nature. 1985;317:629-631.
13. Gregory CD, Murray RJ, Edwards CF, Rickinson AB. Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J Exp Med. 1988;167:1811-1824.
14. Rowe M, Khanna R, Jacob CA, et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol. 1995;25:1374-1384.
15. Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature. 1995;375:685-688.
16. DeCampos-Lima PO, Levitsky V, Brooks J, et al. T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J Exp Med. 1994;179:1297-1305.
17. Fingeroth JD, Weiss JJ, Tedder TF, et al. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci U S A. 1984;81:4510-4516.
18. Morgan AJ. Development of Epstein-Barr Virus Vaccines. Austin, Tex: RG Landes Co; 1995.
19. Li Q, Turk SM, Hutt-Fletcher LM. The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells. J Virol. 1995;69:3987-3994.
20. Spriggs MK, Armitage RJ, Comeau MR, et al. The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation. J Virol. 1996;70:5557-5563.
21. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185-1191.
22. Rooney CM, Smith CA, Ng CYC, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet. 1995;345:9-13.
23. Tosato G, Sgadari C, Taga K, et al. Regression of experimental Burkitt's lymphoma induced by Epstein-Barr virus-immortalized human B cells. Blood. 1994;83:776-784.
24. Sgadari C, Angiolillo AL, Cherney BW, et al. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci U S A. 1996;93:13791-13796.